Nexus Pharmaceuticals is proud to announce the approval of patents covering EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, FDA-approved premixed ephedrine both in vial and syringe formats. The patents, issued by the United States Patent and Trademark Office (USPTO), represent our commitment to bringing innovation and patient safety to medicine.

This list is current as of March 31st, 2023.

The information is not intended to be exhaustive, and is not a representation that the patents listed are the only intellectual property owned by Nexus and applicable to the associated product.

Our EMERPHED® product and methods of manufacture and use are covered by:

• U.S. Patent No. 11,090,278
• U.S. Patent No. 11,241,400
• U.S. Patent No. 11,426,369
• U.S. Patent No. 11,464,752
• U.S. Patent No. 11,478,436
• U.S. Patent No. 11,571,398
• Other U.S. and international patent protection pending